A Nigerian agency, Ash Biomedical Diagnostics Ltd., has introduced the manufacturing of seven of its own-brand diagnostic medication to handle and deal with HIV, malaria, hepatitis, and being pregnant.
The seven merchandise embody ABD HIVChek, MalChek, MalChek Plus, HepaQuik, HepaQuik Duo, PregSure, and FlaviQuik.
The merchandise comprise 12 Stock Keeping Units (SKUs) overlaying 4 essential healthcare testing areas together with HIV, malaria, hepatitis, and being pregnant.
Its Managing Director, Adetoyese Shodeinde, in a press release issued Monday, confused that the achievement mirrored years of deliberate funding in high quality, regulatory compliance, and product improvement.
Shodeinde defined that among the many latest additions now accessible nationwide have been FlaviQuik, designed for Hepatitis C fast testing, and HepaQuik Duo, which allows twin screening for Hepatitis B and Hepatitis C utilizing one take a look at, supporting healthcare suppliers and screening programmes in figuring out people who might require additional medical analysis throughout a single affected person encounter.
Shodeinde stated for Nigerians, the importance of the milestone prolonged past product availability, including that it represents continued progress in the direction of strengthening confidence in regionally developed healthcare options whereas increasing entry to fast diagnostics able to supporting earlier illness detection.
He confused that NAFDAC registration offered the formal regulatory foundation for the merchandise to be marketed in Nigeria.
Shodeinde added, “Our vision has always been bigger than producing diagnostic kits. We are building confidence in Nigerian healthcare manufacturing by ensuring that every product carrying the Ash Biomedical name meets the standards required for quality, reliability and national regulatory approval.”
He said that Ash Biomedical’s expanded hepatitis portfolio arrived as elevated hepatitis screening continued to attract nationwide and international consideration.
The managing director stated by means of FlaviQuik and HepaQuik Duo, Ash Biomedical was contributing extra fast diagnostic choices that supported healthcare professionals in screening sufferers extra effectively.
Shodeinde stated the corporate’s rising hepatitis portfolio complemented its broader dedication to growing sensible diagnostic options that made high quality testing extra accessible throughout Nigeria.
Founded in 2011, Ash Biomedical has steadily grown from a Nigerian diagnostics firm right into a recognised producer with merchandise reaching healthcare establishments throughout the federation.
The firm has delivered 15 million take a look at kits over 15 years by means of greater than 66 authorities and institutional contracts throughout 27 states, whereas its merchandise have reached all 36 states of Nigeria.
Independent hospital evaluations carried out by the APIN Reference Laboratory, NISA Premier, Garki Hospital, Police Clinics, and the National Hospital, Abuja, discovered 100 per cent concordance between Ash Biomedical rapid-test outcomes and reference laboratory findings throughout HIV, hepatitis B, being pregnant, and malaria testing within the evaluated samples.
For the corporate, Shodeinde stated these achievements offered necessary proof that native manufacturing and high quality diagnostics might efficiently coexist inside Nigeria’s evolving healthcare panorama.
He revealed that the agency was concurrently advancing the event of its diagnostics manufacturing facility in Idu, Abuja, which was in its remaining part of development and tools set up.
Shodeinde said that with the construction in progress, manufacturing tools being put in, and cleanroom improvement advancing, the corporate anticipated to fee the manufacturing facility by the primary quarter of 2027.
Adedayo Akinwale
Follow us on:
